Literature DB >> 26907877

Interspinous spacers versus posterior lumbar interbody fusion for degenerative lumbar spinal diseases: a meta-analysis of prospective studies.

Yifeng Cai1, Jiaquan Luo2, Junjun Huang3, Chengjie Lian3, Hang Zhou2, Hao Yao1, Peiqiang Su4.   

Abstract

PURPOSE: Our aim is to evaluate the safety and effectiveness of interspinous spacers versus posterior lumbar interbody fusion (PLIF) for degenerative lumbar spinal diseases.
METHODS: A comprehensive literature search was performed using PubMed, Web of Science and Cochrane Library through September 2015. Included studies were performed according to eligibility criteria. Data of complication rate, post-operative back visual analogue scale (VAS) score, Oswestry Disability Index (ODI) score, estimated blood loss (EBL), operative time, length of hospital stay (LOS), range of motion (ROM) at the surgical, proximal and distal segments were extracted and analyzed.
RESULTS: Ten studies were selected from 177 citations. The pooled data demonstrated the interspinous spacers group had a lower estimated blood loss (weighted mean difference [WMD]: -175.66 ml; 95 % confidence interval [CI], -241.03 to -110.30; p < 0.00001), shorter operative time (WMD: -55.47 min; 95%CI, -74.29 to -36.65; p < 0.00001), larger range of motion (ROM) at the surgical segment (WMD: 3.97 degree; 95%CI, -3.24 to -1.91; p < 0.00001) and more limited ROM at the proximal segment (WMD: -2.58 degree; 95%CI, 2.48 to 5.47; p < 0.00001) after operation. Post-operative back VAS score, ODI score, length of hospital stay, complication rate and ROM at the distal segment showed no difference between the two groups.
CONCLUSIONS: Our meta-analysis suggested that interspinous spacers appear to be a safe and effective alternative to PLIF for selective patients with degenerative lumbar spinal diseases. However, more randomized controlled trials (RCT) are still needed to further confirm our results.

Entities:  

Keywords:  Degenerative lumbar spinal diseases; Interspinous spacer; Meta-analysis; PLIF

Mesh:

Year:  2016        PMID: 26907877     DOI: 10.1007/s00264-016-3139-x

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  16 in total

1.  Evaluation of the mobility of adjacent segments after posterior thoracolumbar fixation: a biomechanical study.

Authors:  L Bastian; U Lange; C Knop; G Tusch; M Blauth
Journal:  Eur Spine J       Date:  2001-08       Impact factor: 3.134

Review 2.  Adjacent segment disease after lumbar or lumbosacral fusion: review of the literature.

Authors:  Paul Park; Hugh J Garton; Vishal C Gala; Julian T Hoff; John E McGillicuddy
Journal:  Spine (Phila Pa 1976)       Date:  2004-09-01       Impact factor: 3.468

Review 3.  Posterior lumbar interbody fusion.

Authors:  Christian P DiPaola; Robert W Molinari
Journal:  J Am Acad Orthop Surg       Date:  2008-03       Impact factor: 3.020

4.  Biomechanical effect of different lumbar interspinous implants on flexibility and intradiscal pressure.

Authors:  Hans-Joachim Wilke; J Drumm; K Häussler; C Mack; W-I Steudel; A Kettler
Journal:  Eur Spine J       Date:  2008-06-27       Impact factor: 3.134

5.  2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group.

Authors:  Andrea D Furlan; Victoria Pennick; Claire Bombardier; Maurits van Tulder
Journal:  Spine (Phila Pa 1976)       Date:  2009-08-15       Impact factor: 3.468

6.  Interspinous spacer decompression (X-STOP) for lumbar spinal stenosis and degenerative disk disease: a multicenter study with a minimum 3-year follow-up.

Authors:  Fabrizio Puzzilli; Roberto Gazzeri; Marcelo Galarza; Massimiliano Neroni; Konstantinos Panagiotopoulos; Andrea Bolognini; Giorgio Callovini; Umberto Agrillo; Alex Alfieri
Journal:  Clin Neurol Neurosurg       Date:  2014-07-14       Impact factor: 1.876

7.  Decompression and Coflex interlaminar stabilization compared with decompression and instrumented spinal fusion for spinal stenosis and low-grade degenerative spondylolisthesis: two-year results from the prospective, randomized, multicenter, Food and Drug Administration Investigational Device Exemption trial.

Authors:  Reginald J Davis; Thomas J Errico; Hyun Bae; Joshua D Auerbach
Journal:  Spine (Phila Pa 1976)       Date:  2013-08-15       Impact factor: 3.468

8.  Grade 1 spondylolisthesis and interspinous device placement: removal in six patients and analysis of current data.

Authors:  Parker E Bohm; Karen K Anderson; Elizabeth A Friis; Paul M Arnold
Journal:  Surg Neurol Int       Date:  2015-04-02

9.  High failure rate of the interspinous distraction device (X-Stop) for the treatment of lumbar spinal stenosis caused by degenerative spondylolisthesis.

Authors:  Olaf J Verhoof; Johannes L Bron; Frits H Wapstra; Barend J van Royen
Journal:  Eur Spine J       Date:  2007-09-11       Impact factor: 3.134

Review 10.  Controversies about interspinous process devices in the treatment of degenerative lumbar spine diseases: past, present, and future.

Authors:  Roberto Gazzeri; Marcelo Galarza; Alex Alfieri
Journal:  Biomed Res Int       Date:  2014-04-13       Impact factor: 3.411

View more
  4 in total

1.  SPINAL SPECIAL EDITION EDITORIAL.

Authors:  Andrew Quaile
Journal:  Int Orthop       Date:  2016-06       Impact factor: 3.075

2.  Transforaminal Lumbar Interbody Fusion with Rigid Interspinous Process Fixation: A Learning Curve Analysis of a Surgeon Team's First 74 Cases.

Authors:  Patrick Doherty; Arthur Welch; Jason Tharpe; Camille Moore; Chris Ferry
Journal:  Cureus       Date:  2017-05-30

3.  Three-Dimensional Volumetric Changes and Clinical Outcomes after Decompression with DIAM™ Implantation in Patients with Degenerative Lumbar Spine Diseases.

Authors:  Cheng-Yu Li; Mao-Yu Chen; Chen-Nen Chang; Jiun-Lin Yan
Journal:  Medicina (Kaunas)       Date:  2020-12-21       Impact factor: 2.430

4.  Response to: Comment on "Controversies about Interspinous Process Devices in the Treatment of Degenerative Lumbar Spine Diseases: Past, Present, and Future".

Authors:  Roberto Gazzeri; Marcelo Galarza; Alex Alfieri
Journal:  Biomed Res Int       Date:  2017-09-18       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.